Halozyme Therapeutics HALO Prepaid Expenses, Non-Current
Prepaid Expenses, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's prepaid expenses, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's prepaid expenses, non-current?
- Halozyme Therapeutics (HALO) reported prepaid expenses, non-current of $50.92M in Q1 2026.
- How has Halozyme Therapeutics's prepaid expenses, non-current changed year-over-year?
- Halozyme Therapeutics's prepaid expenses, non-current decreased by 8.4% year-over-year, from $55.61M to $50.92M.
- What is the long-term trend for Halozyme Therapeutics's prepaid expenses, non-current?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's prepaid expenses, non-current has grown at a 30.7% compound annual growth rate (CAGR), from $14.07M to $53.55M.
- What does prepaid expenses, non-current mean?
- These are payments made for goods or services that will provide economic benefits to the company beyond the next twelve months. This category often includes long-term deposits or multi-year service agreements. It represents capital committed to future operations that is not immediately available as cash.